Citations

Clear

3942 citation(s) found for "To, Van".

Racial and Ethnic Variation in Perceptions of VA Mental Health Providers are Associated With Treatment Retention Among Veterans With PTSD
Spoont, Michele , Nelson, David , Ryn, Michelle van , Alegrı́a, Margarita , van Ryn, Michelle

Mayo Clinic

Medical Care | August 11, 2017 | Volume: 55 | Issue: Suppl 2 | Pages: S33-S42

10.1097/mlr.0000000000000755 | PMID 28806364 Get It

Background: Veterans with posttraumatic stress disorder (PTSD) who seek mental health care in the Veterans Health Administration frequently discontinue treatment prematurely. Early discontinuation of mental health treatment is more common among Veterans with PTSD who are of minority race or ethnicity. Objectives: To determine whether retention in individual therapy or pharmacotherapy among Veterans with PTSD are associated with patients’ ratings of their mental health providers, and if those associations differ depending on Veteran race or ethnicity. Research Design: Latino, African American, and white Veterans (n=2452) who participated in a prospective national cohort study of Veterans with PTSD at the beginning of an episode of care were surveyed immediately following Veterans’ PTSD diagnoses and 6 months later. Pharmacy and mental health service utilization were abstracted from Veterans Health Administration administrative databases for 6 months postdiagnosis. Retention in treatments were modeled using logistic regression among Veterans who initiated individual therapy or pharmacotherapy. Demographics, treatment need, treatment-related beliefs, treatment process measures, and ratings of mental health providers were considered as predictors. Results: Ratings of mental health providers, more than treatment beliefs, were associated with treatment retention. Among African American Veterans, retention in pharmacotherapy was reduced if the provider was perceived as not having helped manage medication side-effects (odds ratio, 0.36; confidence interval, 0.16–0.80). All Latino Veterans but one (99% or n=64) who rated their therapist as not caring discontinued individual psychotherapy. Conclusions: Ratings of mental health providers were associated with treatment retention. The salience of specific provider behaviors to treatment retention varied by Veteran race or ethnicity.
Quantifying the Effects of Prior Acetyl-Salicylic Acid on Sepsis-Related Deaths: An Individual Patient Data Meta-Analysis Using Propensity Matching*
Trauer, James M. , Muhi, Stephen , McBryde, Emma S. , Harbi, Shmeylan Al, Arabi, Yaseen M. , Boyle, Andrew , Cartin‐Ceba, Rodrigo , Chen, Yung‐Tai , Gajić, Ognjen, Godsell, Jack , Gong, Michelle N. , Kor, Daryl J. , Lösche, Wolfgang, McAuley, Daniel F. , O’Neal, Hollis R. , Otto, Gordon P , Soßdorf, Maik, Tsai, Min-Juei, Valerio-Rojas, Juan Carlos , Poll, Tom van der , Ware, Lorraine B. , Widmer, Andreas F. , Wiewel, Maryse A. , Winning, Johannes, Eisen, Damon P. , Trauer, James, Harbi, Shmeylan A. Al , Chen, Wei, Falcone, Marco , Gajic, Ognjen , Osthoff, Michael Friedrich , Violi, Francesco , Arabi, Yaseen M

Mayo Clinic

Critical Care Medicine | August 10, 2017 | Volume: 45 | Issue: 11 | Pages: 1871-1879

10.1097/ccm.0000000000002654 | PMID 28799949 Get It

Objective: The primary objective was to conduct a meta-analysis on published observational cohort data describing the association between acetyl-salicylic acid (aspirin) use prior to the onset of sepsis and mortality in hospitalized patients. Study Selection: Studies that reported mortality in patients on aspirin with sepsis with a comparison group of patients with sepsis not on prior aspirin therapy were included. Data Sources: Fifteen studies described hospital-based cohorts (n = 17,065), whereas one was a large insurance-based database (n = 683,421). Individual-level patient data were incorporated from all selected studies. Data Extraction: Propensity analyses with 1:1 propensity score matching at the study level were performed, using the most consistently available covariates judged to be associated with aspirin. Meta-analyses were performed to estimate the pooled average treatment effect of aspirin on sepsis-related mortality. Data Synthesis: Use of aspirin was associated with a 7% (95% CI, 2–12%; p = 0.005) reduction in the risk of death as shown by meta-analysis with considerable statistical heterogeneity (I 2 = 61.6%). Conclusions: These results are consistent with effects ranging from a 2% to 12% reduction in mortality risk in patients taking aspirin prior to sepsis onset. This association anticipates results of definitive studies of the use of low-dose aspirin as a strategy for reduction of deaths in patients with sepsis.
Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis
Alberts, Rudi , Vries, Elisabeth M. G. de, Goode, Elizabeth C. , Jiang, Xiaojun , Sampaziotis, Fotis , Rombouts, Krista , Böttcher, Katrin , Folseraas, Trine , Weismüller, Tobias J. , Alexander, Graeme, Alvaro, Domenico , Bergquist, Annika , Björkström, Niklas K. , Beuers, Ulrich , Boberg, Kirsten Muri , Bowlus, Christopher L. , Bragazzi, Maria Consiglia , Chazouillères, Olivier , Cheung, Angela , Dalekos, Georgios, Eaton, John E. , Eksteen, Bertus , Ellinghaus, David , Färkkilâ, Martti , Festen, Eleonora A. , Floreani, Annarosa , Franceschet, I., Gotthardt, Daniel , Hoek, Bart van , Holm, Kristian , Hov, Johannes R. , Imhann, Floris , Juran, Brian D., Lenzen, Henrike , Marschall, Hanns–Ulrich , Marzioni, Marco , Melum, Espen , Milkiewicz, Piotr , Müller, Tobias , Parés, Albert , Rupp, Christian , Rust, Christian, Sandford, Richard , Schrumpf, Erik, Silverberg, Mark S. , Srivastava, Brijesh, Sterneck, Martina , Teufel, Andreas , Vallier, Ludovic , Verheij, Joanne , Vila, Arnau Vich , Vries, Boudewijn de, Zachou, Kalliopi , Chapman, Roger W. , Manns, Michael P. , Rushbrook, Simon, Anderson, Carl A. , Karlsen, Tom H. , Ponsioen, Cyriel Y. , Weersma, Rinse K. , Eaton, John, Lazaridis, Konstantinos N. , Ellinghaus, David , Bowlus, Christopher L , Marzioni, Marco , Mason, Andrew L. , Wang, Weiwei , Bjornsson, Einar Stefan , Carbone, Marco , Dalekos, Georgios, Hirschfield, Gideon M. , Hohenester, Simon D. , Invernizzi, Pietro , Lieb, Wolfgang , Liu, Jimmy Z. , Schramm, Christoph , Schreiber, Stefan , Pinzani, Massimo , Franke, André , Bergquist, Annika , Milkiewicz, Piotr , Alvaro, Domenico , Hov, Johannes R , Anderson, Carl A

Mayo Clinic

Gut | August 4, 2017 | Volume: 67 | Issue: 8 | Pages: 1517-1524

10.1136/gutjnl-2016-313598 | PMID 28779025 Get It

Objective Primary sclerosing cholangitis (PSC) is a genetically complex, inflammatory bile duct disease of largely unknown aetiology often leading to liver transplantation or death. Little is known about the genetic contribution to the severity and progression of PSC. The aim of this study is to identify genetic variants associated with PSC disease progression and development of complications. Design We collected standardised PSC subphenotypes in a large cohort of 3402 patients with PSC. After quality control, we combined 130 422 single nucleotide polymorphisms of all patients—obtained using the Illumina immunochip—with their disease subphenotypes. Using logistic regression and Cox proportional hazards models, we identified genetic variants associated with binary and time-to-event PSC subphenotypes. Results We identified genetic variant rs853974 to be associated with liver transplant-free survival (p=6.07×10–9). Kaplan-Meier survival analysis showed a 50.9% (95% CI 41.5% to 59.5%) transplant-free survival for homozygous AA allele carriers of rs853974 compared with 72.8% (95% CI 69.6% to 75.7%) for GG carriers at 10 years after PSC diagnosis. For the candidate gene in the region, RSPO3, we demonstrated expression in key liver-resident effector cells, such as human and murine cholangiocytes and human hepatic stellate cells. Conclusion We present a large international PSC cohort, and report genetic loci associated with PSC disease progression. For liver transplant-free survival, we identified a genome-wide significant signal and demonstrated expression of the candidate gene RSPO3 in key liver-resident effector cells. This warrants further assessments of the role of this potential key PSC modifier gene.
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Crump, Michael , Neelapu, Sattva S. , Farooq, Umar , Neste, Éric Van Den, Westin, Jason R. , Link, Brian K. , Hay, Annette E. , Zhu, Liting , Navale, Lynn, Wiezorek, Jeff, Go, William Y., Gisselbrecht, Christian , Link, Brian K , Farooq, Umar , Westin, Jason R , Kuruvilla, John , Cerhan, James R. , Boussetta, Sami , Feng, Lei , Maurer, Matthew J.

Mayo Clinic

Blood | August 3, 2017 | Volume: 130 | Issue: 16 | Pages: 1800-1808

10.1182/blood-2017-03-769620 | PMID 28774879 Get It

Key Points SCHOLAR-1 is the first patient-level analysis of outcomes of refractory DLBCL from 2 large randomized trials and 2 academic databases. SCHOLAR-1 demonstrated poor outcomes in patients with refractory DLBCL, supporting a need for more effective therapies for these patients.
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasiv
Hendry, Shona , Salgado, Roberto , Gevaert, Thomas, Russell, Prudence A. , John, Tom, Thapa, Bibhusal , Estrada, Mónica V. , González-Ericsson, Paula I. , Solomon, Benjamin , Solinas, Cinzia , Eynden, Gert G. G. M. Van den, Preusser, Matthias , Hainfellner, Johannes A. , Pruneri, Giancarlo , Vingiani, Andrea , Demaria, Sandra , Symmans, Fraser, Nucíforo, Paolo , Comerma, Laura , Thompson, E. Aubrey , Kim, Seong-Rim , Schnitt, Stuart J. , Colpaert, Cécile , Scherer, Stefan, Viale, Giuseppe , Sirtaine, Nicolas , Penault‐Llorca, Frédérique, Sugie, Tomohagu, Fineberg, Susan , Paik, Soonmyung , Richardson, Andrea L., Wang, Yihong , Chmielik, Ewa , Brock, Jane B. , Johnson, Douglas B. , Wienert, Stephan, Bossuyt, Veerle , Michiels, Stefan , Ternès, Nils, Burchardi, Nicole, Klauschen, Frederick , Watson, Peter H. , Nelson, Brad H. , O’Toole, Sandra A., Larsimont, Denis , Wind, Roland de, Curigliano, Giuseppe , André, Fabrice , Vijver, Marc J. van de , Rojo, Federico , Floris, Giuseppe , Bedri, Shahinaz , Sparano, Joseph A. , Rimm, David L. , Kos, Zuzana , Hewitt, Stephen M. , Farshid, Gelareh , Loibl, Sibylle , Allison, Kimberly H. , Adams, Sylvia , Willard‐Gallo, Karen , Gandhi, Leena , Moreira, André L. , Hirsch, Fred R. , Dieci, Maria Vittoria , Urbanowicz, María, Brčić, Iva , Korski, Konstanty, Gaire, Fabien, Koeppen, Hartmut , Lo, Amy, Rebelatto, Marlon C., Steele, Keith E. , Zha, Jiping, Emancipator, Kenneth , Juco, Jonathan, Loi, Sherene , Fox, Stephen B. , Symmans, W. Fraser , John, Thomas , Wang, Yihong , Gonzalez-Ericsson, Paula I , Curigliano, Giuseppe , Sparano, Joseph A , Nelson, Brad H , Preusser, Matthias , André, Fabrice , Symmans, W Fraser , Loi, Sherene , John, Tom, Christie, Michael , Van de Vijver, Koen , Sanders, Melinda E. , Allory, Yves , Lakhani, Sunil R. , Sotiriou, Christos P. , Ignatiadis, Michail , Badve, Sunil , Pierce, Robert Hamilton , Srinivasan, Ashok , Richardson, Andrea L. , Balko, Justin M. , Luen, Stephen James , Savas, Peter Stephen , Criscitiello, Carmen , Lacroix‐Triki, Magali , Nielsen, Torsten O. , Singh, Baljit , Tung, Nadine , Horlings, Hugo , Lo, Amy, Giltnane, Jennifer Margaret , Denkert, Carsten , Reis‐Filho, Jorge S. , Pruneri, Giancarlo , Rimm, David , Dieci, Maria Vittoria , Nuciforo, Paolo , Solomon, Benjamin J

Mayo Clinic

Advances in Anatomic Pathology | August 2, 2017 | Volume: 24 | Issue: 5 | Pages: 235-251

10.1097/pap.0000000000000162 | PMID 28777142 Get It

Assessment of tumor-infiltrating lymphocytes (TILs) in histopathologic specimens can provide important prognostic information in diverse solid tumor types, and may also be of value in predicting response to treatments. However, implementation as a routine clinical biomarker has not yet been achieved. As successful use of immune checkpoint inhibitors and other forms of immunotherapy become a clinical reality, the need for widely applicable, accessible, and reliable immunooncology biomarkers is clear. In part 1 of this review we briefly discuss the host immune response to tumors and different approaches to TIL assessment. We propose a standardized methodology to assess TILs in solid tumors on hematoxylin and eosin sections, in both primary and metastatic settings, based on the International Immuno-Oncology Biomarker Working Group guidelines for TIL assessment in invasive breast carcinoma. A review of the literature regarding the value of TIL assessment in different solid tumor types follows in part 2. The method we propose is reproducible, affordable, easily applied, and has demonstrated prognostic and predictive significance in invasive breast carcinoma. This standardized methodology may be used as a reference against which other methods are compared, and should be evaluated for clinical validity and utility. Standardization of TIL assessment will help to improve consistency and reproducibility in this field, enrich both the quality and quantity of comparable evidence, and help to thoroughly evaluate the utility of TILs assessment in this era of immunotherapy.
The Disputed Discovery of Facial and Trigeminal Nerve Function: Revisiting the Contributions of Herbert Mayo and Charles Bell
Carlson, Matthew L. , Bradley, James , Tubbs, R. Shane , Gompel, Jamie J. Van

Mayo Clinic

Otology & Neurotology | August 2, 2017 | Volume: 38 | Issue: 9 | Pages: 1376-1381

10.1097/mao.0000000000001535 | PMID 28777228 Get It

Background: The first description of the voluntary motor function of the facial nerve and separate sensory-motor contributions of the trigeminal nerve is most commonly attributed to Charles Bell. However, a review of the original scientific accounts and subsequent historical publications question the validity of this credit. The objective of the present historical analysis is to clarify the contributions of Herbert Mayo toward discovering the functions of the fifth and seventh cranial nerves and to raise awareness of this historical controversy within the medical literature. Methods: Review of Charles Bell's and Herbert Mayo's original dissertations published between 1821 and 1823, and subsequent reports relevant to these primary works. Results: Bell's submissions to the Royal Society of London in 1821 and 1822 describe the seventh nerve as the “respiratory nerve of the face” responsible for involuntary coordination of facial movement with the organs of respiration. Separately, Bell states that the fifth nerve is responsible for sensibility and voluntary movement of the facial muscles. In these accounts, Bell only peripherally alludes to the motor function of the seventh nerve and often comments inaccurately on fifth and seventh cranial nerve innervation. In contrast, in 1822 and 1823, Herbert Mayo first accurately and unequivocally defined the voluntary motor function of the facial nerve and sensory-motor function of the trigeminal nerve on the basis of his detailed experiments. The ultimate transfer of acknowledgment to Bell was rooted in surreptitious reworking of Bell's original dissertations and personal attacks against Mayo rather than arguments of scientific merit. Conclusion: Several notable clinicians and anatomists have contributed to our current understanding of the anatomy and physiology of the facial and trigeminal nerves, including Charles Bell; however, Herbert Mayo should be remembered for first providing a more accurate and clear description of their separate functions.
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinoma
Hendry, Shona , Salgado, Roberto , Gevaert, Thomas, Russell, Prudence A. , John, Tom, Thapa, Bibhusal , Estrada, Mónica V. , González-Ericsson, Paula I. , Sanders, Melinda, Solomon, Benjamin , Solinas, Cinzia , Eynden, Gert G. G. M. Van den, Preusser, Matthias , Hainfellner, Johannes A. , Pruneri, Giancarlo , Vingiani, Andrea , Demaria, Sandra , Symmans, Fraser, Nucíforo, Paolo , Comerma, Laura , Thompson, E. Aubrey , Kim, Seong-Rim , Schnitt, Stuart J. , Colpaert, Cécile , Scherer, Stefan, Viale, Giuseppe , Sirtaine, Nicolas , Sugie, Tomohagu, Fineberg, Susan , Paik, Soonmyung , Richardson, Andrea L., Wang, Yihong , Chmielik, Ewa , Brock, Jane, Johnson, Douglas B. , Wienert, Stephan, Bossuyt, Veerle , Michiels, Stefan , Ternès, Nils, Burchardi, Nicole, Savas, Peter, Klauschen, Frederick , Watson, Peter H. , Nelson, Brad H. , O’Toole, Sandra A., Larsimont, Denis , Wind, Roland de, Curigliano, Giuseppe , André, Fabrice , Vijver, Marc J. van de , Rojo, Federico , Floris, Giuseppe , Bedri, Shahinaz , Sparano, Joseph A. , Rimm, David L. , Kos, Zuzana , Hewitt, Stephen M. , Farshid, Gelareh , Loibl, Sibylle , Allison, Kimberly H. , Adams, Sylvia , Willard‐Gallo, Karen , Gandhi, Leena , Hirsch, Fred R. , Dieci, Maria Vittoria , Urbanowicz, María, Brčić, Iva , Korski, Konstanty, Gaire, Fabien, Koeppen, Hartmut , Lo, Amy, Rebelatto, Marlon C., Steele, Keith E. , Zha, Jiping, Emancipator, Kenneth , Juco, Jonathan, Loi, Sherene , Fox, Stephen B. , Symmans, W. Fraser , John, Thomas , Wang, Yihong , Gonzalez-Ericsson, Paula I , Curigliano, Giuseppe , Sparano, Joseph A , Nelson, Brad H , Preusser, Matthias , André, Fabrice , Symmans, W Fraser , Loi, Sherene , John, Tom, Christie, Michael , Van de Vijver, Koen , Allory, Yves , Lakhani, Sunil R. , Sotiriou, Christos P. , Ignatiadis, Michail , Badve, Sunil , Pierce, Robert Hamilton , Penault-Llorca, Frederique Madeleine , Srinivasan, Ashok , Richardson, Andrea L. , Balko, Justin M. , Luen, Stephen James , Savas, Peter Stephen , Criscitiello, Carmen , Lacroix‐Triki, Magali , Nielsen, Torsten O. , Singh, Baljit , Tung, Nadine , Horlings, Hugo , Moreira, Andre M. , Lo, Amy, Giltnane, Jennifer Margaret , Denkert, Carsten , Reis‐Filho, Jorge S. , Pruneri, Giancarlo , Rimm, David , Dieci, Maria Vittoria , Nuciforo, Paolo , Solomon, Benjamin J

Mayo Clinic

Advances in Anatomic Pathology | August 2, 2017 | Volume: 24 | Issue: 6 | Pages: 311-335

10.1097/pap.0000000000000161 | PMID 28777143 Get It

Assessment of the immune response to tumors is growing in importance as the prognostic implications of this response are increasingly recognized, and as immunotherapies are evaluated and implemented in different tumor types. However, many different approaches can be used to assess and describe the immune response, which limits efforts at implementation as a routine clinical biomarker. In part 1 of this review, we have proposed a standardized methodology to assess tumor-infiltrating lymphocytes (TILs) in solid tumors, based on the International Immuno-Oncology Biomarkers Working Group guidelines for invasive breast carcinoma. In part 2 of this review, we discuss the available evidence for the prognostic and predictive value of TILs in common solid tumors, including carcinomas of the lung, gastrointestinal tract, genitourinary system, gynecologic system, and head and neck, as well as primary brain tumors, mesothelioma and melanoma. The particularities and different emphases in TIL assessment in different tumor types are discussed. The standardized methodology we propose can be adapted to different tumor types and may be used as a standard against which other approaches can be compared. Standardization of TIL assessment will help clinicians, researchers and pathologists to conclusively evaluate the utility of this simple biomarker in the current era of immunotherapy.
The use of highly crosslinked polyethylene in total knee arthroplasty
Brown, Timothy S. , Berry, Daniel J. , Berry, Daniel J , Citters, Douglas W. Van , Abdel, Matthew P.

Mayo Clinic

The Bone & Joint Journal | August 2, 2017 | Volume: 99-B | Issue: 8 | Pages: 996-1002

10.1302/0301-620x.99b8.bjj-2017-0028.r1 | PMID 28768774 Get It

Advances in polyethylene (PE) in total hip arthroplasty have led to interest and increased use of highly crosslinked PE (HXLPE) in total knee arthroplasty (TKA). Biomechanical data suggest improved wear characteristics for HXLPE inserts over conventional PE in TKA. Short-term results from registry data and few clinical trials are promising. Our aim is to present a review of the history of HXLPEs, the use of HXLPE inserts in TKA, concerns regarding potential mechanical complications, and a thorough review of the available biomechanical and clinical data.Cite this article: Bone Joint J 2017;99-B:996–1002.
Abstract 5930: Osteoblasts protect AML cells from cytarabine-induced death
Sterner, Rosalie M. , Dudakovic, Amel , Wijnen, André J. van , van Wijnen, Andre J , Kremer, Kimberly N. , Westendorf, Jennifer J. , Hedin, Karen E.

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: 5930-5930

10.1158/1538-7445.am2017-5930 Get It

Abstract The hematological malignancy acute myeloid leukemia (AML) interacts closely with osteoblasts within the protective bone marrow microenvironment. The bone marrow microenvironment protects tumor cells from chemotherapies, which can prevent sufficient eradication of tumor cells. To study the role of osteoblasts in the bone marrow microenvironment, our lab utilized a co-culture model of osteoblasts (MC3T3 osteoblast cell line) and acute myelogenous leukemia cells (KG1a AML cell line or AML patient samples from bone marrow aspirates). Osteoblasts were cultured with AML cells, or AML cells were cultured alone; AML cells were challenged with the standard chemotherapeutic agent cytarabine (Ara-C) at doses of 0µM, 0.1µM, 0.5µM, 1µM, 5µM, or 10µM in the presence or absence of osteoblasts; and AML cells were assayed by flow cytometry to assess cell death via annexin-V staining. Our lab has previously found that differentiating osteoblasts protect AML cells from an apoptosis inducing agent naturally present in the bone marrow. We now show that osteoblasts are also capable of protecting AML cells from the standard chemotherapeutic cytarabine. In addition, we have found that treatment of osteoblasts with the histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA) prevents these treated osteoblasts from protecting AML cells from cytarabine treatment, which is consistent with our lab’s previous findings that HDACi treatment inhibits protection of AML cells from an apoptosis inducing agent naturally present in the bone marrow. We have preliminary data that indicates that TAZS89A over-expression, a constitutively active form of TAZ, which is a transcriptional modulator that regulates osteoblast differentiation, may be sufficient to inhibit osteoblast mediated protection of AML cells from cytarabine. This finding would be consistent with the HDACi manipulated Nherf1-protein phosphatase 1α-TAZ signaling pathway that we have previously found to be sufficient to inhibit protection of AML cells from an apoptosis inducing agent naturally present in the bone marrow. Overall, these studies have delivered insights into the role of osteoblasts in protecting AML cells from chemotherapy in the bone marrow microenvironment and begun the characterization of mechanisms and targets responsible for the protective effects of osteoblasts. Manipulating differentiating osteoblasts within the bone marrow microenvironment therapeutically could aid in more complete destruction of the tumor cell burden and improve patient survival. Citation Format: Rosalie M. Sterner, Kimberly N. Kremer, Amel Dudakovic, Jennifer J. Westendorf, Andre J. van Wijnen, Karen E. Hedin. Osteoblasts protect AML cells from cytarabine-induced death [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5930. doi:10.1158/1538-7445.AM2017-5930
Abstract 425: SMRT® Sequencing of full-length androgen receptor isoforms in prostate cancer reveals previously hidden drug resistant variants
Ho, Yeung, Etten, Jamie L. Van, Li, Yingming , Tseng, Elizabeth , Hon, Ting, Silverstein, Kevin A.T. , Wang, Liewei , Kohli, Manish , Hillman, David W. , Henzler, Christine M. , Yang, Rendong , Clark, Tyson A. , Wang, Liguo , Dehm, Scott M.

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: 425-425

10.1158/1538-7445.am2017-425 Get It

Abstract Prostate cancer is the most frequently diagnosed male cancer. For prostate cancer that has progressed to an advanced or metastatic stage, androgen deprivation therapy (ADT) is the standard of care. ADT inhibits activity of the androgen receptor (AR), a master regulator transcription factor in normal and cancerous prostate cells. The major limitation of ADT is the development of castration-resistant prostate cancer (CRPC), which is almost invariably due to transcriptional re-activation of the AR. One mechanism of AR transcriptional re-activation is expression of AR-V7, a truncated, constitutively active AR variant (AR-V) arising from alternative AR pre-mRNA splicing. Noteworthy, AR-V7 is being developed as a predictive biomarker of primary resistance to androgen receptor (AR)-targeted therapies in CRPC. Multiple additional AR-V species are expressed in clinical CRPC, but the extent to which these may be co-expressed with AR-V7 or predict resistance is not known. Here we utilized long read sequencing to identify and quantify AR isoforms expressed in CRPC. To unambiguously characterize all AR isoforms, we prepared Iso-Seq™ libraries via 3’ rapid amplification of cDNA ends (RACE) with RNA isolated from prostate cancer cell lines and xenograft tissues using a forward primer anchored in AR exon 1. 3’RACE reactions were subjected to single molecule, real-time (SMRT®) long-read sequencing with a Pacific Biosciences RSII System. Our work identified AR-V9 as a truncated isoform that is frequently co-expressed with AR-V7 in CRPC. Mechanistically, our work re-annotated AR-V7 and AR-V9 mRNAs, showing these two species shared a common 3’ terminal exon containing separate splice acceptor sites. Taking into account this new information, novel siRNAs and antibodies which could distinguish between AR-V7 and AR-V9 were designed, validated and used to measure the relative expression of these two AR isoforms in CRPC cells with a view to determining the potential of AR-V9 as a predictive biomarker of primary resistance to AR-targeted therapies. Citation Format: Manish Kohli, Yeung Ho, David W. Hillman, Jamie L. Van Etten, Christine Henzler, Rendong Yang, Yingming Li, Elizabeth Tseng, Ting Hon, Tyson A. Clark, Liguo Wang, Kevin Silverstein, Liewei Wang, Scott M. Dehm. SMRT® Sequencing of full-length androgen receptor isoforms in prostate cancer reveals previously hidden drug resistant variants [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 425. doi:10.1158/1538-7445.AM2017-425